Whole-body 18F-FDG PET in recurrent or metastatic nasopharyngeal carcinoma

Journal of Nuclear Medicine

Volumn 46, Issue 5, 2005, Pages 770-774

  Yen, Ruoh Fang ^a,b   Hong, Ruey Long ^a   Tzen, Kai Yuan ^a   Pan, Mei Hsiu ^a   Chen, Tony Hsiu Hsi ^b  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Nasopharyngeal carcinoma; Survival analysis; Whole body 18F FDG PET

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ACCURACY; ADOLESCENT; ADULT; AGED; ARTICLE; CANCER STAGING; CHEMOTHERAPY; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; HYPERMETABOLISM; MAJOR CLINICAL STUDY; MALE; NASOPHARYNX CARCINOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECURRENT CANCER; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; TAIWAN; WHOLE BODY SCINTISCANNING; CARCINOMA; METASTASIS; METHODOLOGY; MIDDLE AGED; NASOPHARYNX TUMOR; PROGNOSIS; REPRODUCIBILITY; RISK ASSESSMENT; RISK FACTOR; SCINTISCANNING; TREATMENT OUTCOME; TUMOR RECURRENCE; WHOLE BODY COUNTING;

ADOLESCENT; ADULT; AGED; CARCINOMA; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; WHOLE-BODY COUNTING;

EID: 20644433108     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Huang DP. Epidemiology of nasopharyngeal carcinoma. Ear Nose Throat J. 1990;69:222-225.
2. Liu MT, Hsieh CY, Chang TH, et al. Prognostic factors affecting, the outcome of nasopharyngeal carcinoma. Jpn J Clin Oncol 2003;33:501-508.
3. Farias TP, Dias FL, Lima RA, et al. Prognostic factors and outcome for nasopharyngeal carcinoma. Arch Otolaryngol Head Neck Surg 2003;125:754-799.
4. Chong VF, Fan YF. Detection of recurrent nasopharyngeal carcinoma: MR imaging versus CT. Radiology. 1997;202:463-470.
5. Ng SH, Chang JTC, Ko SF, et al. MRI in recurrent nasopharyngeal carcinoma. Neuroradiology. 1999;41:855-862.
6. Olmi P, Fallai C, Colagrande S, et al. Staging and follow-up of nasopharyngeal carcinoma: magnetic resonance imaging versus computerized tomography. Int J Radiat Oncol Biol Phys 1995;32:795-300.
7. Kao CH, ChangLai SP, Chieng PU, et al. Detection of recurrent or persistent nasopharyngeal carcinomas after radiotherapy with 18-fluoro-2- deoxyglucose positron emission tomography and comparison with computed tomography. J Clin Oncol. 1998;16:3550-3555.
8. 18F-fluorodeoxyglucose in detecting residual/recurrent squamous cell carcinoma of the head and neck. AJNR 1998;19:1189-1190.
9. Kao CH, Shiau YC, Shen YY, et al. Detection of recurrent or persistent nasopharyngeal carcinomas after radiotherapy with technetium-99m methoxyisobutylisonitrile single photon emission computed tomography and computed tomography: comparison with 18-fluoro-2-deoxyglucose positron emission tomography. Cancer. 2002;94:1981-1986.
10. Yen RF, Hung RL, Pan MH, et al. 18-Fluoro-2-deoxyglucose positron emission tomography in detecting residual/recurrent nasopharyngeal carcinomas and comparison with magnetic resonance imaging. Cancer 2003;98:283-287.
11. Bengel FM, Ziegler SI, Avril N, et al. Whole-body positron emission tomography in clinical oncology: comparison between attenuation-corrected and uncorrected images. Eur J Nucl Med 1997;24:1091-1098.
12. Coleman RE, Laymon CM, Turkington TG. FDG imaging of lung nodules: a phantom study comparing SPECT, camera-based PET and dedicated PET. Radiology 1999;210:823-828.
13. Nuyts J, Stroobants S, Dupont P, et al. Reducing loss of image quality because of the attenuation artifact in uncorrected PET whole-body images. J Nucl Med 2002;43:1054-1062.
14. Mitsuhashi N, Hayakawa K, Hasegawa M, et al. Clinical FDG-PET in diagnosis and evaluation of radiation response of patients with nasopharyngeal tumor. Anticancer Res. 1998;18:2827-2832.
15. Greven KM, Williams DW 3rd, Keyes JW Jr, et al. Positron emission tomography of patients with head and neck carcinoma before and after high dose irradiation. Cancer 1994;74:1355-1359.
16. Chaiken L, Rege S, Hoh C, et al. Positron emission tomography with fluorodeoxyglucose to evaluate tumor response and control after radiation therapy. Int J Radiat Oncol Biol Phys. 1993;27:455-464.
17. van den Brekel MW, Stel HV, Castelijns JA, et al. Cervical lymph node metastasis: assessment of radiologic criteria. Radiology. 1990;177:379-384.
18. Chua DTT, Sham JST, Kwong DLW, et al. Retropharyngeal lymphadenopathy in patients with nasopharyngeal carcinoma. Cancer 1997;79:869-877.
19. Bailet JW, Abemayor E, Jabour BA, et al. Positron emission tomography: a new, precise imaging modality for detection of primary head and neck tumors and assessment of cervical adenopathy. Laryngoscope 1992;102:281-288.
20. Kao CH, Hsieh JF, Tsai SC, et al. Comparison of 18-fluoro-2-deoxyglucose positron emission tomography and computed tomography in detection of cervical lymph node metastases of nasopharyngeal carcinoma. Ann Otol Rhinol Laryngol 2000;109:1130-1134.
21. Brink I, Klenzner T, Krause T, et al. Lymph node staging in extracranial head and neck cancer with FDG PET: appropriate uptake period and size-dependence of the results. Nuklearmedizin. 2002;41:108-113.
22. Mancuso AA, Drane WE, Mukherji S. The promise FDG in diagnosis and surveillance of head and neck cancer. Cancer 1994;74:1193-1195.
23. Huang CJ, Leung SW, Lian SL, et al. Patterns of distant metastases in nasopharyngeal c arcinoma. Kaohsiung J Med Sci. 1996;12:229-234.
24. 18F- fluorodeoxyglucose positron emission tomography in patients with head and neck cancer. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2002;93:202-207.
25. Pai M, Park CH, Suh JH, et al. Fluorine-18 fluorodeoxyglucose imaging using dual-head coincidence positron emission tomography without attenuation correction in patients with head and neck cancer. Clin Nucl Med. 1999;24:495-500.
26. Barrington SF, Maisey MN. Skeletal muscle uptake of fluorine-18-FDG: effect of oral diazepam. J Nucl Med 1996;37:1127-1129.
27. Mukherji SK, Drane WE, Mancuso AA, et al. Occult primary tumors of the head and neck: detection with 2-[F-18]fluoro-2-deoxy-d-glucose SPECT. Radiology. 1996;199:761-766.
28. 18F-FDG PET in patients with head and neck cancer: a probability analysis. Eur J Nucl Med Mol Imaging 2003;30:562-571.
29. Hong RL, Lin CY, Tin LL, et al. Comparison of clinical and molecular surveillance in patients with advanced nasopharyngeal carcinoma after primary therapy. Cancer. 2004;100:1429-1437.